Header Logo

Connection

Ravindre Panchia to Female

Back to Details
This is a "connection" page, showing publications Ravindre Panchia has written about Female.
Ravindre Panchia
Connection Strength
0,634
Female
  1. Preferences for HIV pre-exposure prophylaxis formulations and delivery among young African women: results of a discrete choice experiment. J Int AIDS Soc. 2025 Feb; 28(2):e26422.
    View in: PubMed
    Score: 0,023
  2. High recent PrEP adherence with point-of-care urine tenofovir testing and adherence counselling among young African women: results from the INSIGHT cohort. J Int AIDS Soc. 2024 Dec; 27(12):e26389.
    View in: PubMed
    Score: 0,023
  3. Bisexuality among Men who have Sex with Men in Sub-Saharan Africa: Findings from the HPTN 075 Study. AIDS Behav. 2025 Mar; 29(3):747-759.
    View in: PubMed
    Score: 0,023
  4. Interest in Oral Pre-exposure Prophylaxis Among Men Who Have Sex with Men and Transfeminine Persons in HPTN 075, a Multi-center HIV Prevention Study in Sub-Saharan Africa (2015-2017). AIDS Behav. 2025 Feb; 29(2):411-419.
    View in: PubMed
    Score: 0,023
  5. Interest in I-PrEP and Willingness to Participate in Clinical Trials Among Men and Transfeminine Persons Who have Sex with Men in Sub-Saharan Africa: Quantitative and Qualitative Findings from HPTN 075. AIDS Behav. 2024 Jul; 28(7):2361-2377.
    View in: PubMed
    Score: 0,022
  6. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022 05 07; 399(10337):1779-1789.
    View in: PubMed
    Score: 0,019
  7. Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. AIDS. 2022 02 01; 36(2):257-265.
    View in: PubMed
    Score: 0,019
  8. HIV Incidence Among Pregnant and Nonpregnant Women in the FACTS-001 Trial: Implications for HIV Prevention, Especially PrEP Use. J Acquir Immune Defic Syndr. 2021 12 01; 88(4):376-383.
    View in: PubMed
    Score: 0,019
  9. Sexually transmitted infections among HIV serodiscordant partners: A secondary analysis of HIV Prevention Trial Network 052. Int J STD AIDS. 2021 11; 32(13):1204-1211.
    View in: PubMed
    Score: 0,018
  10. Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study. Clin Infect Dis. 2021 07 01; 73(1):60-67.
    View in: PubMed
    Score: 0,018
  11. Likely clinical depression and HIV-related decline in antiretroviral therapy untreated women who seroconverted during participation in microbicide trials in sub-Saharan Africa. Int J STD AIDS. 2021 06; 32(7):620-628.
    View in: PubMed
    Score: 0,018
  12. HIV incidence in a multinational cohort of men and transgender women who have sex with men in sub-Saharan Africa: Findings from HPTN 075. PLoS One. 2021; 16(2):e0247195.
    View in: PubMed
    Score: 0,018
  13. Uptake of antiretroviral treatment and viral suppression among men who have sex with men and transgender women in sub-Saharan Africa in an observational cohort study: HPTN 075. Int J Infect Dis. 2021 Mar; 104:465-470.
    View in: PubMed
    Score: 0,018
  14. The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa (HPTN 075). J Int AIDS Soc. 2020 10; 23 Suppl 6:e25600.
    View in: PubMed
    Score: 0,017
  15. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531.
    View in: PubMed
    Score: 0,017
  16. Healthcare-related stigma among men who have sex with men and transgender women in sub-Saharan Africa participating in HIV Prevention Trials Network (HPTN) 075 study. AIDS Care. 2020 08; 32(8):1052-1060.
    View in: PubMed
    Score: 0,017
  17. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481.
    View in: PubMed
    Score: 0,017
  18. HIV testing and the HIV care continuum among sub-Saharan African men who have sex with men and transgender women screened for participation in HPTN 075. PLoS One. 2019; 14(5):e0217501.
    View in: PubMed
    Score: 0,016
  19. Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075. AIDS Behav. 2019 Jan; 23(1):289-294.
    View in: PubMed
    Score: 0,015
  20. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690.
    View in: PubMed
    Score: 0,015
  21. Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2018 11; 18(11):1241-1250.
    View in: PubMed
    Score: 0,015
  22. Antiretroviral drug use and HIV drug resistance among MSM and transgender women in sub-Saharan Africa. AIDS. 2018 06 19; 32(10):1301-1306.
    View in: PubMed
    Score: 0,015
  23. HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr. 2018 04 15; 77(5):484-491.
    View in: PubMed
    Score: 0,014
  24. Comparison of Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Participants Enrolled in a Multinational Clinical Trial: HPTN 052. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):388-393.
    View in: PubMed
    Score: 0,014
  25. HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One. 2017; 12(6):e0178594.
    View in: PubMed
    Score: 0,014
  26. Association of HIV diversity and virologic outcomes in early antiretroviral treatment: HPTN 052. PLoS One. 2017; 12(5):e0177281.
    View in: PubMed
    Score: 0,014
  27. Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clin Trials. 2017 05; 18(3):100-109.
    View in: PubMed
    Score: 0,014
  28. Pulmonary TB: varying radiological presentations in individuals with HIV in Soweto, South Africa. Trans R Soc Trop Med Hyg. 2017 03 01; 111(3):132-136.
    View in: PubMed
    Score: 0,013
  29. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2017 Jan 01; 74(1):112-116.
    View in: PubMed
    Score: 0,013
  30. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 09 01; 375(9):830-9.
    View in: PubMed
    Score: 0,013
  31. Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr. 2016 07 01; 72(3):304-9.
    View in: PubMed
    Score: 0,013
  32. Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. J Acquir Immune Defic Syndr. 2015 Oct 01; 70(2):212-7.
    View in: PubMed
    Score: 0,012
  33. Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy. J Acquir Immune Defic Syndr. 2015 Jun 01; 69(2):138-44.
    View in: PubMed
    Score: 0,012
  34. Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
    View in: PubMed
    Score: 0,012
  35. CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention. PLoS One. 2014; 9(3):e90754.
    View in: PubMed
    Score: 0,011
  36. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
    View in: PubMed
    Score: 0,011
  37. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0,011
  38. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,010
  39. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. Vaccine. 2013 Jan 21; 31(5):777-83.
    View in: PubMed
    Score: 0,010
  40. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011 Sep; 15(9):1194-200, i.
    View in: PubMed
    Score: 0,009
  41. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,008
  42. Perceptions and knowledge about AIDS among family planning clinic attenders in Johannesburg. S Afr Med J. 1992 Jan 18; 81(2):71-4.
    View in: PubMed
    Score: 0,002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.